| Code | CSB-RA023984MB11HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to FTL-001, targeting TNFRSF9 (Tumor Necrosis Factor Receptor Superfamily Member 9), also known as 4-1BB or CD137. TNFRSF9 is an inducible costimulatory receptor expressed primarily on activated T cells and natural killer cells, playing a critical role in enhancing cellular immune responses. Upon binding to its ligand 4-1BBL, TNFRSF9 promotes T cell proliferation, cytokine production, and survival, making it a key regulator of adaptive immunity. This pathway has garnered significant interest in cancer immunotherapy and autoimmune disease research, as modulation of TNFRSF9 signaling can enhance anti-tumor immunity or influence inflammatory responses.
FTL-001 represents an investigational therapeutic antibody designed to engage the TNFRSF9 pathway for immune modulation. This biosimilar provides researchers with a reliable tool for investigating TNFRSF9 biology, exploring costimulatory mechanisms in immune cell activation, and studying potential therapeutic interventions in oncology and immunological disorders. The antibody supports various research applications aimed at understanding T cell-mediated immunity and developing novel immunotherapeutic strategies.
There are currently no reviews for this product.